Objective: To compare the cytologic preparations of 130 cervical specimens (from women of various ethnicities at high risk for human papillomavirus [HPV] infection) using the SurePath (SP) collection system with specimens gathered using the ThinPrep (TP) system, as processed on the Cobas 4800 analyzer, to determine which collection method more accurately identifies HPV infection.
The human papillomavirus (HPV) is the most common sexually transmitted infection in both sexes worldwide. 1 Recent data from the Centers for Disease Control and Prevention (CDC) indicate that approximately 79 million people are currently infected with HPV and 14 million individuals annually are newly infected with HPV in the United States.
2,3 HPV-associated cervical cancer rates vary by population, with variations observed in association with ethnicity and socioeconomic status (SES). [4] [5] [6] [7] Higher incidence rates have been reported among Hispanic, African American, American Indian, and Alaskan Native women. 8 The annual number of new cervical cancer cases is 12,966, and the annual number of deaths due to cervical cancer is 6605. 3 Many early HPV-related studies focused on testing of individuals from fairly limited geographical distributions; these studies tended to have fairly homogenous populations. Bronx County in New York City, NY, presents a unique opportunity to provide clinical data from a remarkably ethnically diverse population. Nearly one-third of all Bronx residents are foreign born. 9 The Latin and African American 
Materials and Methods
From October 2015 through May 2016, women aged 18 years to 65 years who attended colposcopic or well-women clinics at Montefiore Medical Center, Bronx, NY, were prospectively recruited for this study. We performed the study following the Montefiore Medical Center institutional review board (IRB)-approved protocol (2014-3600) and met all standards of New York State validation for the method tested. Informed consent was obtained from all patients according to the aforementioned protocol.
Two cervical specimens (collected via TP and SP systems, respectively) were obtained from each subject on the same visit. The SP-collected specimen was obtained first, followed by the TP-collected specimen. Our rationale for this order was to produce minimal impact to the flow of clinical specimens (our institution uses the SP method). From the SP-collected specimen, a cytologic slide was prepared before HPV testing was performed. We tested the residual SP-cell concentrate and alternate TP-collected specimens for HR-HPV using the Cobas 4800 HPV test (TP slides are not used for cytologic evaluation in our institute). Also, we collected demographic information on the study participants from the laboratory information system.
The test targets the highly conserved L1 region of the HPV genome using primer pairs directed to amplify 14 HR-HPV genotypes. Genotype-specific fluorescent oligonucleotide probes bind to polymorphic regions within the sequence amplified by these primers. also simultaneously detects b-globin as an internal cellularity control for the assay. We performed the test following the manufacturer-provided instructions. A portion of the SPcollected specimen was used for the standard cytologic analysis as a part of routine clinical care. We then used the vial remnant for this study, after we cleared it for use and deidentified it.
The SP-collected and TP-collected specimens used in the study were given paired identifiers unrelated to the patient, for results comparison. The SP-collected and TP-collected specimens were tested on the same day to eliminate possible time-sensitive limited bias. 
Results

Comparative Testing
We tested a total of 130 cases in this prospective study; the results were concordant for overall HR-HPV status in 93.8% of cases (n ¼ 122). One test had an invalid result in SPcollected and TP-collected specimens, most likely attributable to poor specimen and/or DNA quality. Seven HR-HPV discordant cases had HR-HPV-positive results in SP and HR-HPV-negative results in TP-collected specimens ( Table 1) .
In 6 of the 7 cases with discrepant results, QIAGEN Hybrid Capture testing was performed, and follow-up patient biopsies also were analyzed. From the 6 cases tested, 5 of them (83%) resulted in a positive HPV genotype result via QIAGEN Hybrid Capture testing. We also compared cytologic and subsequent biopsy reports for these cases ( Table 2) . For 1 patient, no follow-up biopsy material was identified in the clinical records of the hospital.
Genotype Results
Of those 93.8% of cases in which both assays demonstrated the presence of HR-HPV, the genotype identified by the instrument was concordant in all but 1 specimen (99%). This specimen tested positive for HPV 16 using TP and tested positive for HPV 16 and other HR-HPV types using SP. This case by itself can be observed to be concordant regarding HPV 16 and only discordant regarding the detection of the presence of another HR genotype. This finding can most likely be explained by slightly higher cellularity, which was obtained on the first-pass SP collection.
PCR Cycle Threshold (CT) Values
T-TEST We performed testing on 2 specimen types, assuming unequal variance with 99% confidence level. The mean value for SP-collected specimens is 29.04 and for TPcollected specimens is 31.80. We noted statistically significant lower CT values in SP-collected specimens using standard 2 � 2 and univariate analysis (P ¼ .001; Figure 1 ). Again, all variables were limited in this analysis to the greatest degree possible. However, because the integrity of the clinical portion of the collection using SP was not to be changed, it is possible that the initial collection produced more material compared with the second cervical exfoliation. 
Cytology and Cobas HPV Results on SP-Collected Specimens
The SP Cobas results for different cytologic diagnosis categories are shown in Table 3 . The results correlated well, and the percentage of HR-HPV-positive cases increased with increasing cytologic abnormality. Of 27 patients with negative cytologic results, 11% tested HR-HPV positive. This finding increased to 100% HR-HPV positive in cases diagnosed as atypical squamous cell of uncertain significance-cannot rule out high grade (ASCUS-HG), high-grade intraepithelial lesion (HSIL), and squamous cell carcinoma.
Summary of Findings
To our knowledge, ours was the first attempt in the literature to correlate HPV genotypic data from an ethnically diverse Bronx population with cytopathologic diagnosis across the diagnostic spectrum. We detected high-risk HPV (HR-HPV) genotypes in a multiethnic population of women being treated at the Montefiore Medical Center, Bronx, NY. We used the Cobas 4800 HPV test in SP-collected liquid cytologic specimens and compared the findings from TP-collected specimens (the latter method had been approved by the FDA at the time we performed this study). We used dual collection at the bedside and concurrently ran test specimens collected in SP and TP media. We performed all collection and subsequent testing on the same day, to avoid any time-sensitive bias. The results from this study were robust; we used them to obtain approval of using SP collection for HPV genotyping according to the rigorous standards of New York State.
Discussion
In this prospective analysis of the performance of the Cobas 4800 HPV test on 2 different collection media in an ethnically diverse population, we observed no impact of the collection media on assay performance. In fact the HPV detection rate in the formalin-fixed SP-collected specimens apparently increased to greater than the HPV detection rate in TP media. Also, we observed a statistically significant lower CT value with Cobas testing of SP-collected specimens, which suggested higher cellularity and sensitivity compared with TP-collected specimens. Although the shortcoming of the study design using a secondary collection can be considered, a concordance rate of nearly 94% was achieved, with genotypic correlation greater than 99%.
When this study was performed, the use of SP-collected specimens with the Cobas instrument was not yet FDA approved; despite this, our study results prove that SPcollected specimen concentrates are a completely adequate source for HR-HPV testing, even in a patient population with a high prevalence of HPV. QIAGEN Hybrid Capture testing and follow-up biopsies of discrepant results suggest that the HPV detected in the SP-collected specimens evinces truepositive test results. The results of this study also demonstrate the importance and clinical usefulness of laboratory-developed testing and off-label testing. These assays allow for the creation of institution-and populationspecific methods that can be rigorously validated for use in laboratories and may provide overall stronger performance than narrowly designed methods with FDA approval. Our results also demonstrate that many of these off-label validations drive ultimate FDA approval as the manufacturers become slowly aware of individual laboratory needs, as is represented in this case.
We were interested to note that cases designated "HSIL" or "rule out HSIL" on cytologic testing tended to have tested HPV 16 positive. In contrast, cases with lower-grade cytologic results (negative, atypical squamous cells of undetermined significance [ASCUS], or low-grade squamous intraepithelial lesions [LSIL]), if they tested positive for HPV, were more likely to also test positive for the other HR-HPV types. We will be interested to find out whether this trend continues on further clinical testing because it may indicate further updating testing guidelines based on cytologic findings.
There are very limited data comparing HPV detection rates of specimens collected via SP and TP media from an ethnically diverse population. Studies that examine the HPV-positivity rate by comparing these 2 collection methodologies mostly have discovered comparable diagnostic accuracies; some authors have found statistically higher rates of HR-HPV in SP-collected specimens when the cytologic diagnosis was ASCUS or LSIL. [24] [25] [26] Nevertheless, and as previously discussed herein, many authors have reported that specimen adequacy rates while using TP collection methods were lower than those determined while using SP methods. [15] [16] [17] In our population there appears to be a higher-thanpreviously-reported percentage of HPV-positive results in the cytologic-testing category of "negative [results] with reactive changes." [21] [22] [23] This finding may reflect the genetic diversity of our study population, whose demographics were similar to those of the surrounding population of the Bronx county. African American and Latino patients represented 30% and 26% of patients, respectively, whereas whites made up only 17% of the study group. The remainder of the study participants belonged to other ethnic groups, including "mixed ethnicity" and those who did not identify their ethnicity. Alternately, the reactive changes may truly represent early morphologic evidence of HPV infection.
There is a high risk of HPV infection among the patient population of our institution. In this study, we discovered the increased sensitivity of the SP method in detecting squamous lesions, as well as apparently increased sensitivity of the SP method for HPV detection. As a result of this information, our institution has believes that SP collection methods are optimal for testing specimens from our patients. As we embark on personalized precision medicine, we strongly believe that guidelines for any population must use evidence-based conclusions that are generalizable to the specific patient demographics and subsequently may be modified, foreseeing changes in growth, shifts, and changes in the diversity of the patient population. The results of this prospective study proved the validity of the use of SP-collected specimens for HPV detection. Our results also continue to demonstrate the robustness of the Cobas 4800 platform on a variety of specimen types.
TP-collected and SP-collected specimens have become the most commonly used liquid-based cytologic specimens. Both provide the opportunity for additional testing for HPV after the production of a cytologic slide. The SP methodology conveys several distinct advantages over the TP methodology. The ability of the SP system to manage mucus by a cell-enrichment process has been shown to result in less-diminished cell recovery. 15 SP has demonstrated fewer unsatisfactory smears 16 and also has demonstrated increased CINI and CINII detection. 17 The cytopathologists at Montefiore Medical Center, recognizing the distinct challenges of serving and caring for several populations in the Bronx that are at high risk for contracting HPV, have preferred the SP liquid-based cytologic test for these reasons.
However, although there are certain advantages to using SP for the production of a cytologic slide, there are theoretical drawbacks to the use of the SP test for a molecular-based assay. The SP formulation involves using formaldehyde and ethanol for cellular fixation. Formaldehyde has detrimental effects on the secondary structure of DNA and has been demonstrated to negatively affect the recovery of DNA 18 and its usefulness in molecular testing. 19, 20 Therefore, we sought to perform a side-by-side analysis of the SP and TP systems in molecular testing of routine HPV cytopathologic specimens, in a population with marked ethnic diversity compared with the populations studied in previous analyses.
In closing, we hope that our findings may help healthcare professionals to further formulate specific screening guidelines for cervical cancer in ethnically diverse inner city populations because the resources, SES, risk factors, and patient culture of those populations are distinct from those of the general population of the United States. LM 
